Dicerna Strengthens Board of Directors with Two New Appointments
August 16 2018 - 6:00PM
Business Wire
Industry Veterans J. Kevin Buchi and Cynthia
Smith Add Key Industry and Commercial Operations Expertise
Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer
of investigational ribonucleic acid interference (RNAi)
therapeutics, today announced the appointments of J. Kevin Buchi,
former chief executive officer of Cephalon, Inc., and TetraLogic
Pharmaceuticals Corp., and Cynthia Smith, former chief commercial
officer of ZS Pharma, Inc., to its board of directors. The
appointments are effective immediately and increase the size of
Dicerna’s board to 10 members.
“Kevin and Cynthia are two highly regarded industry veterans and
their appointments to our board of directors is reflective of our
growth, as we continue to advance our GalXC™-based pipeline,
including our lead program, DCR-PHXC for the treatment of all forms
of primary hyperoxaluria,” said Douglas M. Fambrough, Ph.D.,
president and chief executive officer of Dicerna. “Kevin is an
accomplished executive and director who brings with him extensive
industry experience. As such, he will provide valuable insights
regarding our operations, strategy, and corporate governance.
Cynthia possesses significant expertise in the biopharmaceutical
industry most notably in building and leading commercial operations
across multiple therapeutic categories, a key area of future growth
for Dicerna. We are delighted to welcome them both and look forward
to leveraging their knowledge as we move toward achieving our
planned milestones.”
Most recently Mr. Buchi served as president and chief executive
officer of TetraLogic Pharmaceuticals. Before TetraLogic, he served
as corporate vice president of Global Branded Products at Teva
Pharmaceutical Industries Limited from 2011 to May 2012. Mr. Buchi
was chief executive officer of Cephalon, Inc., which was acquired
by Teva in October 2011. Mr. Buchi joined Cephalon in 1991 and,
during his tenure, held various leadership positions, including
chief financial officer and chief operating officer, before
becoming Cephalon's chief executive officer in December 2010. In
addition, Mr. Buchi currently serves as a director of Amneal
Pharmaceuticals Inc. and Benitec Biopharma Ltd. Mr. Buchi has
previously served on the boards of several pharmaceutical
companies, including EPIRUS Biopharmaceuticals, Inc., Alexza
Pharmaceuticals, Inc. and Forward Pharma A/S.
Ms. Smith has more than 20 years of broad leadership experience
within the healthcare industry. Most recently she has served as
chief commercial officer and a member of the executive team of ZS
Pharma, acquired by AstraZeneca in 2015 for approximately $2.7
billion, where she led efforts to transition the company from the
development stage to a commercial enterprise. Prior to joining ZS
Pharma, Ms. Smith served as vice president, market access and
commercial development at Affymax, Inc. Earlier, she held various
senior leadership positions in market access, corporate strategy,
government relations, and external affairs at Merck & Co.
Before beginning her career in the biopharmaceutical industry, Ms.
Smith served as a healthcare policy analyst in the White House
Office of Management and Budget. She previously served on the board
of Nivalis Therapeutics.
About Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company
focused on the discovery and development of innovative,
subcutaneously delivered RNAi-based therapeutics for the treatment
of diseases involving the liver, including rare diseases, viral
infectious diseases, chronic liver diseases, and cardiovascular
diseases. Dicerna is leveraging its proprietary GalXC™ RNAi
technology platform to build a broad pipeline in these core
therapeutic areas, focusing on target genes where connections
between target gene and diseases are well understood and
documented. Dicerna intends to discover, develop and commercialize
novel therapeutics either on its own or in collaboration with
pharmaceutical partners. For more information, please visit
www.dicerna.com.
Cautionary Note on Forward-Looking Statements
This press release includes forward-looking statements. Such
forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially from those
expressed or implied in such statements. Applicable risks and
uncertainties include risks relating to Dicerna’s clinical and
preclinical research and other risks identified under the heading
"Risk Factors" included in the Company’s most recent Form 10-Q
filing and in other future filings with the SEC. The
forward-looking statements contained in this press release reflect
Dicerna's current views with respect to future events, and Dicerna
does not undertake and specifically disclaims any obligation to
update any forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180816005699/en/
Investors:Rx Communications GroupPaula Schwartz,
917-322-2216pschwartz@rxir.comorMedia:SmithSolveAlex Van
Rees, 973-442-1555 ext. 111alex.vanrees@smithsolve.com
Dicerna Pharmaceuticals (NASDAQ:DRNA)
Historical Stock Chart
From Apr 2024 to May 2024
Dicerna Pharmaceuticals (NASDAQ:DRNA)
Historical Stock Chart
From May 2023 to May 2024